Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

Overview of attention for article published in Frontiers in Pharmacology, December 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 161,369 followers.

RT @ChocolatiereP: Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer https://t.co/ooRmn78hX…

New Research: Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer https://t.co/pQjo5TwAAh #pharmacology

RT @ChocolatiereP: Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer https://t.co/ooRmn78hX…

RT @ChocolatiereP: Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer https://t.co/ooRmn78hX…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.